Fluticasone Furoate 0.055% W/W Nasal Spray is a topical nasal drug formulation comprising Fluticasone Furoate at a defined concentration of 0.055% w/w. Development of a nasal spray formulation involves tightly controlled incorporation of the active pharmaceutical ingredient, vehicle, particle or droplet size and distribution, pH, viscosity, microbiological quality, and performance of the device. In addition, it must be compatible with the chosen container-closure system and metering device. For pharmaceutical businesses wishing to broaden their nasal dosage-form range, Fluticasone Furoate 0.055% W/W Nasal Spray can be incorporated into a structured PCD Pharma Franchise portfolio with suitable manufacturing, quality-control, and packaging documentation.
An initial evaluation of the active ingredient, Fluticasone Furoate, includes an assessment of its physicochemical properties. As Fluticasone Furoate is at a relatively low concentration in the formulation, accurate incorporation and uniform dispersion of the active are important considerations.
The proposed formulation design may include an aqueous vehicle as well as buffering agents, suspending or dispersing agents, viscosity modifiers, surfactants, preservatives (where appropriate), and additional pharmaceutical excipients.
Excipient selection is based on their intended technological role and compatibility with Fluticasone Furoate. Preformulation studies can assist in assessing parameters such as solubility, particle size, dispersion characteristics, pH, viscosity, and physical stability.
For suspension-based formulations, control of the dispersed active component is crucial. Particle-size distribution can influence sedimentation rate, ability to redisperse, spray performance, and dose uniformity.
The formulation is finalized after physical stability, chemical stability, and compatibility with the chosen nasal spray delivery system are thoroughly evaluated.
The active pharmaceutical ingredient and pharmaceutical excipients are identified, tested, and weighed for accurate dispensing as part of the manufacturing process. This step is critical, especially where the API is present at a low level.
In the case of a suspension formulation, the active pharmaceutical ingredient may require appropriate particle-size reduction through milling or sieving before incorporation. Controlled particle-size processing is investigated in accordance with the raw-material specification and formulation needs.
The use of a wetting or dispersing agent can encourage uniform dispersion of the active component in the liquid vehicle. Dispersion conditions and sequence of addition are optimized as part of formulation development.
Soluble excipients are prepared separately in the liquid vehicle, which can then be combined with the dispersed active pharmaceutical ingredient, and mixed under controlled conditions. Mixing speed, duration, temperature, and sequence may impact on the ability of the formulation to disperse and the stability of the dispersed particles.
High-shear homogenization is an option to facilitate formulation uniformity without interfering with intended particle-dispersion properties.
Quality control in-process controls include appearance, pH, viscosity, and bulk uniformity. The bulk is handled in controlled conditions prior to filling into final containers.
The delivery device for a nasal spray is an inherent part of the finished product. Container, pump, dip tube, actuator, and metering device must work cohesively to produce a reproducible spray.
Parameters such as delivered volume, weight per spray, pump volume, and number of sprays are assessed, and the spray pattern characterized as part of the product-specific device evaluation. For suspension-based products, uniformity of API distribution is an important consideration.
Pump output, actuation force, and reproducibility are evaluated, as well as priming and repriming characteristics. Compatibility with the container-closure system is studied to ensure that the formulation and device components do not adversely interact.
Overall, the combination of device and formulation components should provide reproducible, quality spray characteristics within predefined limits.
The quality control testing of Fluticasone Furoate 0.055% W/W Nasal Spray product involves chemical, physical, microbiological, and device-related performance testing.
API identification and assay are conducted using validated methods with appropriate sensitivity and precision given the low API concentration.
Finished-product testing can include pH, appearance, viscosity, delivered dose, spray weight, spray pattern, and other relevant performance metrics. Particle size and redispersibility may also be studied if appropriate.
For suspension products, globule size distribution in the bulk suspension can be examined. The microbial quality of the formulation is relevant, including the need for preservative activity, use-dilutions, and microbial limits.
Stability of the API in the formulation, as well as microbiological stability if relevant, can be monitored through stability studies. Analytical, microbiological, and device-specific tests are documented in batch records and reviewed.
A stability program is instigated to confirm whether Fluticasone Furoate 0.055% W/W Nasal Spray retains the agreed specifications throughout the shelf life.
The stability profile can include assay, degradation products, appearance, pH, viscosity, microbial quality, and the physical and functional characteristics of the dispenser. The interaction of the formulation with the dispensing device is studied as part of the stability assessment.
Packaging containers protect the product from environmental impacts such as temperature, humidity, and light. Suitable pharmaceutical-grade bottles and metering devices are selected to accompany the formulation.
Container-closure integrity and leak testing are performed to ensure that the product maintains the required integrity. The injection-moulded pump or other metering device maintains delivery performance over time.
The product label reflects the approved product name, composition, strength, batch number, manufacturing, expiration, and storage instructions, amongst other regulatory requirements.
Stability data supports the storage conditions and shelf life under specific storage conditions.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech